| Name | Title | Contact Details |
|---|
MITER Brands is a prominent North American manufacturer of windows and doors, formed in 2022. The company unites well-known brands such as Milgard, MI Windows and Doors, and PGT Innovations, which was acquired in 2024. MITER Brands is dedicated to manufacturing excellence, innovation, and building strong customer relationships. The company produces a wide range of windows and doors, including impact-resistant options designed for safety in extreme weather conditions. MITER Brands emphasizes custom solutions for builders, contractors, and homeowners, focusing on energy efficiency and design flexibility. With a commitment to innovation, the company utilizes proprietary manufacturing technologies and sustainable design practices. MITER Brands serves residential and commercial markets across the nation, aiming to be the most valued window and door brand in America.
Bank of George emerged with a new brand celebrating our technological advancements in the digital space – GBank! We are proud of our improved digital banking and mobile apps for both your personal and business accounts. With increased functionality and efficiency, we know you will love the new GBank. And as tech advances, so will we. We will never lose sight of the core values that have made us your chosen community bank as we grow. Our goal is to give our clients the highest level of service and care at all times. When they look back and assess their relationship with our institution, the total of all the interactions along their banking journey with GBank equals Your Best Banking Experience Ever!® But it doesnt stop there. Our goal is always to give our colleagues that same level of service and care.
For 27 years and counting, SLAM has been the most authentic brand in basketball storytelling. What started as a magazine in 1994 has now grown into a global lifestyle brand and multimedia property with 20-plus social channels, a burgeoning merchandise division and multiple franchise events annually. With over 16 million engaged followers across the globe, SLAM and its channels reach fans of the NBA, WNBA, college and high school, and the worlds of fashion, sneakers, gaming and more in a unique and trusted voice. The cover of SLAM remains the Holy Grail for basketball players; if you want to play in the NBA or WNBA, you want to be on the cover of SLAM.
BLUEBONNET® Abstract and Title is a locally owned and operated title company located in Brenham and Bellville Texas and serving adjacent counties. We are fully licensed in Washington, Austin, Fayette, Brazos, Grimes, Robertson, Colorado, and Lee Counties, and serve the adjoining counties (such as Waller), regularly. BLUEBONNET® was established to provide a title company focused on the customer and the community. BLUEBONNET® sets itself apart from its competitors by providing excellent customer service in all aspects of the real estate transaction. Our customers actually enjoy the real estate closing process – we know you will too.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.